AI-supported mammography increases breast cancer detection, reduces interval cancers, and substantially lowers radiologist workload versus standard double reading.
Key Details
- 1MASAI trial assigned 105,915 women to AI-assisted or double-reading groups in screening.
- 2AI-assisted mammography decreased interval cancer rate by 12% (1.55 vs. 1.76 per 1,000 women).
- 3Sensitivity was higher for AI (80.5%) compared to double reading (73.8%), with specificity unchanged (98.5% both groups).
- 4AI support resulted in a 44% reduction in screen-reading workload and a 29% increase in cancer detection without increasing false positives.
- 5Improvements were consistent across age and breast density, but not for in-situ cancers.
- 6The study highlights significant relevance amid a shortage of breast radiologists.
Why It Matters
These large-scale findings support integrating AI into breast cancer screening workflows for both higher detection rates and better efficiency, critical as radiology faces workforce challenges. Evidence from randomized trials will influence adoption, reimbursement, and future research.
Source
AuntMinnie
Related News
•Radiology Business
Everlywell Launches Direct-to-Consumer Mammography AI for Breast Cancer Risk
Everlywell now offers the FDA-authorized Clairity Breast AI tool for patients to assess breast cancer risk from their mammograms.
•Radiology Business
Sweden Deploys AI as Standalone Second Reader for Mammography
Three Stockholm hospitals will adopt AI to fully replace radiologist second reads in breast cancer screening.
•Radiology Business
BCRF Launches $100M Fund, Invests in AI Mammography Startup Clairity
BCRF unveils a $100M fund, awarding its first investment to AI mammography company Clairity Inc.